马斯克“量产预告”引爆脑机接口

Core Viewpoint - The brain-machine interface (BMI) industry is transitioning from experimental research to commercial viability, with Neuralink's announcement of mass production in 2026 marking a significant turning point for the sector [1][3]. Group 1: Industry Developments - Neuralink, founded by Elon Musk in 2016, aims to develop high-bandwidth, low-invasiveness brain-machine interface technology to treat neurological diseases and facilitate human-AI coexistence [3]. - As of January 2024, Neuralink completed its first human implantation of a BMI device, with 12 individuals having received the device by September 2025, accumulating over 15,000 hours of usage [3][4]. - The company has demonstrated that clinical trial participants can control devices such as robotic arms and play video games using only their brain signals [4]. Group 2: Market Expectations - The global brain-machine interface market is projected to grow to approximately $12.4 billion by 2034, indicating strong commercial potential [5]. - Neuralink raised over $650 million in 2025 for factory construction and technology scaling, with a post-money valuation of around $9 billion as of June 2025 [5]. - The company plans to expand its technology capabilities, including direct language decoding and visual restoration, with milestones set for 2025 through 2028 [5]. Group 3: Technological Challenges - Despite advancements, the invasive nature of BMIs presents challenges related to biocompatibility and long-term stability, which need to be addressed for widespread adoption [1][6]. - The commercialization of BMIs requires overcoming significant hurdles, including lengthy validation processes and substantial funding needs, as highlighted by industry experts [7][8]. - Competitors like Synchron predict that medical applications of BMIs may take 3 to 5 years for approval, while consumer-grade devices could take 15 to 20 years to become viable [8].